Patents Assigned to NANOVI RADIOTHERAPY APS
-
Patent number: 11331396Abstract: Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1:1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable T1 contrast enhancement (T1˜900 ms) in the rim over at least 3 weeks with clinically observable resolution.Type: GrantFiled: May 24, 2018Date of Patent: May 17, 2022Assignees: TECHNICAL UNIVERSITY OF DENMARK, NANOVI RADIOTHERAPY APSInventors: Thomas Andresen, Rasmus Irming Jølck, Linda Maria Bruun
-
Patent number: 11058780Abstract: The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body.Type: GrantFiled: May 19, 2017Date of Patent: July 13, 2021Assignees: TECHNICAL UNIVERSITY OF DENMARK, NANOVI RADIOTHERAPY APSInventors: Thomas Lars Andresen, Rasmus Irming Jølck, Linda Maria Bruun
-
Publication number: 20200197541Abstract: The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.Type: ApplicationFiled: January 2, 2020Publication date: June 25, 2020Applicants: DANMARKS TEKNISKE UNIVERSITET, NANOVI RADIOTHERAPY APSInventors: Thomas Lars Andresen, Rasmus Irming Jolck, Morten Albrechtsen
-
Patent number: 10561746Abstract: The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.Type: GrantFiled: May 23, 2014Date of Patent: February 18, 2020Assignees: Danmarks Tekniske Universitet, Nanovi Radiotherapy APSInventors: Thomas Lars Andresen, Rasmus Irming Jolck, Morten Albrechtsen
-
Publication number: 20190275174Abstract: The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body.Type: ApplicationFiled: May 19, 2017Publication date: September 12, 2019Applicants: TECHNICAL UNIVERSITY OF DENMARK, NANOVI RADIOTHERAPY APSInventors: Thomas Lars Andresen, Rasmus Irming Jølck, Linda Maria Bruun
-
Publication number: 20160089454Abstract: The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.Type: ApplicationFiled: May 23, 2014Publication date: March 31, 2016Applicants: DANMARKS TEKNISKE UNIVERSITET, NANOVI RADIOTHERAPY APSInventors: Thomas Lars Andresen, Rasmus Irming Jolck, Morten Albrechtsen